TScan Therapeutics appoints Garry Nicholson to board, Stephen Biggar named chair; Barberich retires

TScan Therapeutics, Inc.

Timothy Barberich resigned as director and Chair effective June 12, 2024; no disagreement cited.
Stephen Biggar, M.D., Ph.D., assumed Chair role; Nicholson appointed to Board effective same date.
Garry Nicholson brings 35+ years oncology experience, including former President of Pfizer Oncology.
Stockholders approved Amended 2021 Equity Plan adding 2M shares; non-employee directors granted options for 308,750 shares at $8.88.
Nicholson receives initial option for 71,250 shares, vesting over one year or next annual meeting.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Stephen Biggar

Chairman of the Board

TCRX · TScan Therapeutics, Inc.

Effective: 2024-06-12
Filed: June 14, 2024, 7:59 PM ET

Current member of the Board, Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board, effective as of the Effective Date.

Departed

Timothy Barberich

Chairman of the Board and Director

TCRX · TScan Therapeutics, Inc.

Effective: 2024-06-12
Successor: Stephen Biggar
Filed: June 14, 2024, 7:59 PM ET

On June 12, 2024 (the “Effective Date”), after the conclusion of the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company”), Timothy Barberich, a member and Chairman of the Board of Directors (the “Board”) of the Company, tendered his resignation from the Board and Chairman position thereof, effective immediately.

Appointed

Garry Nicholson

Director

TCRX · TScan Therapeutics, Inc.

Effective: 2024-06-12
Filed: June 14, 2024, 7:59 PM ET

On June 12, 2024, the Board appointed Garry Nicholson to the Board, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Biggar changed role as Chairman of the Board at TScan Therapeutics, Inc..

Action: assumed
Role: Chairman of the Board

Exact text from the filing

Current member of the Board, Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy Barberich resigned as Chairman of the Board and Director at TScan Therapeutics, Inc..

Action: resigned
Role: Chairman of the Board and Director

Exact text from the filing

On June 12, 2024 (the “Effective Date”), after the conclusion of the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company”), Timothy Barberich, a member and Chairman of the Board of Directors (the “Board”) of the Company, tendered his resignation from the Board and Chairman position thereof, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Garry Nicholson was appointed as Director at TScan Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 12, 2024, the Board appointed Garry Nicholson to the Board, effective as of the Effective Date.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-161151

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.